Metastatic colorectal cancer harboring the BRAF V600E mutation is associated with aggressive disease biology and historically poor clinical outcomes. Although chemotherapy combinations such as FOLFOX and FOLFIRI remain standard first-line treatment options, durable responses and long-term survival remain challenging to achieve in this patient population.

The Phase III BREAKWATER trial has already established the clinical value of encorafenib plus cetuximab combined with mFOLFOX6. To further expand treatment flexibility, BREAKWATER Cohort 3 evaluated encorafenib plus cetuximab with FOLFIRI (EC+FOLFIRI) against standard FOLFIRI-based therapy with or without bevacizumab in patients with previously untreated BRAF V600E-mutant mCRC.

Efficacy Outcomes:

• Median PFS: 15.2 vs 8.3 months with EC+FOLFIRI vs control.

• EC+FOLFIRI reduced the risk of disease progression or death by 56%(HR: 0.44; p = 0.0002). 

• Median OS: NE vs 20.3 months (HR: 0.56), 18-month OS rate: 72.0% vs 54.5%.

• ORR: 64.4% vs 39.2%. (odds ratio 2.76 [95% CI 1.42, 5.35; one-sided P=0.001]) 

•  

Safety Outcomes:

• Serious TEAEs: 49% vs 44% 

• Grade 3/4 TEAEs: 70% vs 81% 

• Treatment discontinuation due to AEs: 14% vs 10% 

• No new safety signals observed  

KOL insights-

“Results build on the previously reported positive ORR data, further supporting the meaningful benefit that this encorafenib-based targeted approach may provide for patients with BRAF V600E-mutant mCRC. The combination of significant responses and improved PFS highlights the potential of encorafenib as a potentially practice-changing treatment option for patients and families facing this challenging diagnosis.”– Expert opinion.

Conclusion-

BRAF V600E-mutant metastatic colorectal cancer remains a difficult-to-treat subtype with historically poor survival outcomes. BREAKWATER Cohort 3 demonstrated clinically meaningful and statistically significant ORR and PFS improvements and prolonged OS with EC+FOLFIRI vs control. The safety profile was consistent with that known for each agent, with no new safety signals. EC+FOLFIRI expands practice-changing standard-of-care options to deliver point-centered care for patients with BRAF V600E-mutant mCRC.